|
Antiproliferative effect of NVP-AUY922 against a panel of human breast cancer cell lines |
|||
| Cell line |
ErbB2/ER status |
NVP-AUY922 |
17-AAG |
|
|
|||
| nM |
|||
|
|
|||
| BT-474 |
ErbB2+/ER+ |
3.1 ± 1.4 |
17.4 ± 5.2 |
| BT20 |
ErbB2-/ER- |
4.0 ± 1.4 |
18.9 ± 4.8 |
| MDA-MB-157 |
ErbB2-/ER- |
126 ± 37 |
29.5 ± 20.8 |
| MDA-MB-231 |
ErbB2-/ER- |
7.0 ± 1.7 |
2,057 ± 571 |
| MDA-MB-468 |
ErbB2-/ER- |
6.3 ± 2.6 |
1,657 ± 390 |
| SkBr3 |
ErbB2+/ER- |
3.3 ± 0.9 |
11.9 ± 8.0 |
| MCF-7 |
ErbB2-/ER- |
8.8 ± 1.8 |
69.0 ± 18.3 |
|
The concentrations of NVP-AUY922 and tanespimycin (17-AAG) that inhibit cell number by 50% (GI50) were determined. ErbB2 and estrogen receptor (ER) status is indicated. | |||
Jensen et al. Breast Cancer Research 2008 10:R33 doi:10.1186/bcr1996 |
|||